Get the Stockscreener App
1.295
0.75%
-0.045
Equillium Inc stock is traded at $1.295, with a volume of 33,847.
It is down -0.75% in the last 24 hours and down -28.88% over the past month.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
See More
Previous Close:
$1.34
Open:
$1.35
24h Volume:
33,847
Relative Volume:
0.00
Market Cap:
$77.35M
Revenue:
$45.91M
Net Income/Loss:
$-4.62M
P/E Ratio:
-9.2368
EPS:
-0.1402
Net Cash Flow:
$-21.51M
1W Performance:
-11.33%
1M Performance:
-28.88%
6M Performance:
+177.66%
1Y Performance:
+44.57%
1-Day Range:
$1.30
$1.4094
1-Week Range:
$1.32
$1.6384
52-Week Range:
$0.27
$2.35
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
1.30 | 79.73M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.45 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.17 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
What to expect from Equillium Inc. in the next 30 days2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Will Equillium Inc. stock continue upward momentum2025 Support & Resistance & Risk Controlled Swing Alerts - newser.com
Will Equillium Inc. rebound enough to break evenShare Buyback & Fast Gain Stock Tips - newser.com
How cyclical is Equillium Inc. (0FY) stock compared to rivals2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Real time scanner hits for Equillium Inc. explained2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Is it time to cut losses on Equillium Inc.Weekly Trend Report & Entry Point Strategy Guides - newser.com
Is Equillium Inc. building a consolidation baseEarnings Recap Summary & Capital Efficiency Focused Ideas - newser.com
Will Equillium Inc. price bounce be sustainableMarket Trend Report & Weekly Market Pulse Alerts - newser.com
How to manage a losing position in Equillium Inc.July 2025 Action & Daily Growth Stock Investment Tips - newser.com
Why global investors buy Equillium Inc. (0FY) stockEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
Will Equillium Inc. (0FY) stock keep high P E multiplesTrade Signal Summary & Daily Profit Maximizing Tips - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Equillium (NASDAQ:EQ) - Defense World
BRIEF-Equillium Announces Leadership And Corporate Updates - The Sunday Guardian
Equillium announces leadership changes as it shifts focus to EQ504 - Investing.com
Equillium announces leadership changes as it shifts focus to EQ504 By Investing.com - Investing.com Nigeria
Equillium (EQ) Ends Collaboration with Biocon on Itolizumab - GuruFocus
Equillium, Inc. Announces Leadership Changes and Focus on Advancing EQ504 for Inflammatory Diseases - Quiver Quantitative
Equillium, Inc. Announces Management Changes , Effective October 1, 2025 - MarketScreener
What MACD and RSI say about Equillium Inc.July 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Why Equillium Inc. (0FY) stock stays undervalued2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will a bounce in Equillium Inc. offer an exitTrade Entry Report & Expert Approved Trade Ideas - newser.com
What momentum shifts mean for Equillium Inc.Weekly Gains Summary & Technical Analysis for Trade Confirmation - newser.com
Is Equillium Inc. stock bottoming outWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
Detecting price anomalies in Equillium Inc. with AIMarket Activity Report & AI Forecast for Swing Trade Picks - newser.com
Using RSI to spot recovery in Equillium Inc.July 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
What drives Equillium Inc 0FY stock pricePortfolio Risk Assessment & Low Cost Market Strategies - earlytimes.in
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):